TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences.
TolerogenixX secures seed funding and completes Phase I clinical trial
Info & Contact
Im Neuenheimer Feld 162